Second Merck deal takes Lycera's autoimmune quiver to potential $600m+
This article was originally published in Scrip
Lycera's second collaboration with Merck, which is worth more than $300 million in upfront and future milestone fees plus royalties, gives the Ann Arbor, Michigan-based company a third drug discovery and development program focused on selective small molecule immune-modulators to treat autoimmune diseases.
You may also be interested in...
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.
Aspen Neuroscience, Pandion and iTeos raised $70m, $80m and $125m, respectively. Also, Glide Healthcare closed a €416m ($450m) fund; ElevateBio, Kallyope and SutroVax reveal VC mega-rounds; and Dragonfly adds new funding to its partnering proceeds.